Insights

Security and Supply of Blood Derived Ancillary Materials May Need to Be Rethought in the Era of Novel Viral Outbreaks: A Webinar Hosted by HCATS & Sexton Biotechnologies

Dr. Preti Answers Questions in ISCT’s Talking with Giants

When Robert Preti, PhD, co-founded PCT back in 1999, he already had extensive experience in stem cell processing and other roles from his time with the New York Blood ...

Moving Towards Automated Manufacturing for Cell Therapies

As more cell therapy products reach the “finish line” of U.S. Food and Drug Administration (FDA) approval and new regenerative medicine products begin the clinical ...

Phacilitate 2019 Event Recap

Phacilitate is the world’s largest advanced therapies partnering event, bringing together experts and solution providers from all over the world to create the perfect ...

Bloomberg Law Article: Breakthrough Cancer Therapy Stalls in Manufacturing Bottleneck

In a recent Bloomberg Law article, Robert Preti, PhD, discusses how manufacturing bottlenecks are holding up cancer treatments from going to market. There has been a lot ...

Think Beyond Cleanrooms for a Commercially-Sustainable Future

Maintaining a sterile environment is an absolute must for maintaining product sterility in cell therapy manufacturing. Although the cost of building cleanrooms has ...

Executive Interview - PCT: Manufacturing the Future of Cell Therapies

In an interview published in the May 2017 issue of Drug Development & Delivery, PCT President Robert Preti, PhD, discusses PCT’s founding, differentiators, growth, ...

Moving Toward Controlled, Non-Classified Space For Cell Therapies

Despite the advances the cell therapy industry has made in recent years, commercially viable manufacturing continues to be an elusive challenge. In order for the cell ...

Reducing Idle Capacity Through the Factory of the Future

The following is an excerpt from an article published in the April issue of BioProcess international, entitled “Factories of the Future: Can Patient-Specific Cell ...